Clinical Trials Browser

Recruiting × Multiple Myeloma × Nivolumab × Clear all

NCT03297606 2026-03-04

CAPTUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT06523621 2026-03-04

Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

Phase 2 Recruiting

Multiple Myeloma

NCT02693535 2026-02-13

TAPUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT03017820 2025-10-08

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Phase 1 Recruiting

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic